Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.

Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop EO, Debets R, Joerger M, Odink A, van der Veldt AAM, van der Leest CH, Aerts JGJV, Mathijssen RHJ, Koolen SLW.

J Immunother Cancer. 2019 Jul 19;7(1):192. doi: 10.1186/s40425-019-0669-y.

PMID:
31324223
2.

Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.

Hurkmans DP, Verhoeven JGHP, de Leur K, Boer K, Joosse A, Baan CC, von der Thüsen JH, van Schaik RHN, Mathijssen RHJ, van der Veldt AAM, Hesselink DA.

J Immunother Cancer. 2019 Jul 12;7(1):182. doi: 10.1186/s40425-019-0653-6.

3.

CD45RA+CCR7- CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab.

Kunert A, Basak EA, Hurkmans DP, Balcioglu HE, Klaver Y, van Brakel M, Oostvogels AAM, Lamers CHJ, Bins S, Koolen SLW, van der Veldt AAM, Sleijfer S, Mathijssen RHJ, Aerts JGJV, Debets R.

J Immunother Cancer. 2019 Jun 8;7(1):149. doi: 10.1186/s40425-019-0608-y.

4.

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.

Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1931-1939. doi: 10.1007/s00259-019-04358-9. Epub 2019 Jun 6.

PMID:
31172212
5.

Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40.

Rijnders M, van der Veldt AAM, de Wit R, van Leenders GJLH.

Eur Urol. 2019 Jun;75(6):e160-e161. doi: 10.1016/j.eururo.2019.01.039. Epub 2019 Feb 2. No abstract available.

PMID:
30723047
6.

Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.

Basak EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, Bins S, Oomen-de Hoop E, Wijkhuijs AJM, Besten ID, Sleijfer S, Debets R, van der Veldt AAM, Aerts JGJV, Mathijssen RHJ.

Eur J Cancer. 2019 Mar;109:12-20. doi: 10.1016/j.ejca.2018.12.008. Epub 2019 Jan 14.

PMID:
30654225
7.

PD-L1 Antibody Comparison in Urothelial Carcinoma.

Rijnders M, van der Veldt AAM, Zuiverloon TCM, Grünberg K, Thunnissen E, de Wit R, van Leenders GJLH.

Eur Urol. 2019 Mar;75(3):538-540. doi: 10.1016/j.eururo.2018.11.002. Epub 2018 Nov 27. No abstract available.

PMID:
30497882
8.

[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].

van Zeijl MCT, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Haanen JBAG, Aarts MJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven KJM.

Ned Tijdschr Geneeskd. 2018 Jun 15;162. pii: D2420. Dutch.

PMID:
30040270
9.

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.

Bins S, Basak EA, El Bouazzaoui S, Koolen SLW, Oomen-de Hoop E, van der Leest CH, van der Veldt AAM, Sleijfer S, Debets R, van Schaik RHN, Aerts JGJV, Mathijssen RHJ.

Br J Cancer. 2018 May;118(10):1296-1301. doi: 10.1038/s41416-018-0074-1. Epub 2018 Apr 26.

10.

Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.

Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, Testori A, van Leeuwen BL, van der Veldt AAM, Keilholz U, Eggermont AMM, Verhoef C, Grünhagen DJ.

Eur J Cancer. 2018 Jun;96:25-33. doi: 10.1016/j.ejca.2018.02.022. Epub 2018 Apr 13.

PMID:
29660597
11.

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.

Walraven M, Homs MYV, van der Veldt AAM, Dekker H, Koldenhof J, Honeywell R, Barendrecht A, Sebastian SAE, Parr N, Koekman AC, Voest EE, Roest M, Korporaal SJA, Verheul HMW.

Angiogenesis. 2018 May;21(2):325-334. doi: 10.1007/s10456-018-9598-5. Epub 2018 Mar 12.

13.

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

Rijnders M, de Wit R, Boormans JL, Lolkema MPJ, van der Veldt AAM.

Eur Urol. 2017 Sep;72(3):411-423. doi: 10.1016/j.eururo.2017.06.012. Epub 2017 Jun 20. Review.

PMID:
28645491
14.

Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Verwer EE, Boellaard R, van der Veldt AA.

World J Clin Oncol. 2014 Dec 10;5(5):824-44. doi: 10.5306/wjco.v5.i5.824. Review.

15.

In vivo imaging as a pharmacodynamic marker.

van der Veldt AA, Lammertsma AA.

Clin Cancer Res. 2014 May 15;20(10):2569-77. doi: 10.1158/1078-0432.CCR-13-2666. Review.

16.

Women with silicone breast implants and unexplained systemic symptoms: a descriptive cohort study.

Maijers MC, de Blok CJ, Niessen FB, van der Veldt AA, Ritt MJ, Winters HA, Kramer MH, Nanayakkara PW.

Neth J Med. 2013 Dec;71(10):534-40.

17.

Does drug accumulation in bone explain the efficacy and toxicity of docetaxel in prostate cancer?

van der Veldt AA, Smit EF, Lammertsma AA.

Clin Genitourin Cancer. 2014 Apr;12(2):e63-4. doi: 10.1016/j.clgc.2013.04.035. Epub 2013 Nov 14. No abstract available.

PMID:
24331578
18.

Effects of chemotherapy on the parotid and submandibular glands in head and neck cancer patients treated with chemoradiotherapy.

van der Veldt AA, Smit EF, Comans EF, Lammertsma AA.

Strahlenther Onkol. 2014 Feb;190(2):221-2. doi: 10.1007/s00066-013-0487-y. Epub 2013 Dec 6. No abstract available.

PMID:
24306065
19.

Pituitary gland: do anticancer drugs sit in the Turkish saddle?

van der Veldt AA, Smit EF, Lammertsma AA.

J Clin Oncol. 2014 Mar 10;32(8):851-2. doi: 10.1200/JCO.2013.51.2632. Epub 2013 Nov 12. No abstract available.

PMID:
24220565
20.

Video recording of medical procedures.

van der Veldt AA, Kleijn SA, Nanayakkara PW.

JAMA. 2013 Sep 4;310(9):979-80. doi: 10.1001/jama.2013.194742. No abstract available.

PMID:
24002292
21.

Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [(11)C]docetaxel.

van der Veldt AA, Smit EF, Lammertsma AA.

Front Oncol. 2013 Aug 13;3:208. doi: 10.3389/fonc.2013.00208. eCollection 2013.

22.

Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.

Frings V, de Langen AJ, Yaqub M, Schuit RC, van der Veldt AA, Hoekstra OS, Smit EF, Boellaard R.

Mol Imaging Biol. 2014 Feb;16(1):136-45. doi: 10.1007/s11307-013-0658-3.

PMID:
23813332
23.

Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.

Frings V, van der Veldt AA, Boellaard R, Herder GJ, Giovannetti E, Honeywell R, Peters GJ, Thunnissen E, Hoekstra OS, Smit EF.

PLoS One. 2013 May 24;8(5):e63705. doi: 10.1371/journal.pone.0063705. Print 2013.

24.

Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography.

van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, Comans EF, Rutten HB, Eriksson J, Windhorst AD, Hendrikse NH, Postmus PE, Smit EF, Lammertsma AA.

Clin Cancer Res. 2013 Aug 1;19(15):4163-73. doi: 10.1158/1078-0432.CCR-12-3779. Epub 2013 Apr 25.

25.

Cancer therapy: could a novel test predict the amount of drug that reaches its target?

van der Veldt AA, Smit EF, Lammertsma AA.

Expert Rev Anticancer Ther. 2013 Apr;13(4):377-9. doi: 10.1586/era.13.13. No abstract available.

PMID:
23560831
26.

Reduction in thyroid perfusion after bevacizumab treatment.

van der Veldt AA, Lammertsma AA, Smit EF.

Thyroid. 2013 Oct;23(10):1329-30. doi: 10.1089/thy.2013.0147. Epub 2013 Jul 25. No abstract available.

PMID:
23548042
27.

Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.

Bahce I, Smit EF, Lubberink M, van der Veldt AA, Yaqub M, Windhorst AD, Schuit RC, Thunnissen E, Heideman DA, Postmus PE, Lammertsma AA, Hendrikse NH.

Clin Cancer Res. 2013 Jan 1;19(1):183-93. doi: 10.1158/1078-0432.CCR-12-0289. Epub 2012 Nov 7.

28.

Scheduling of anticancer drugs: timing may be everything.

Van der Veldt AA, Lammertsma AA, Smit EF.

Cell Cycle. 2012 Dec 1;11(23):4339-43. doi: 10.4161/cc.22187. Epub 2012 Oct 3.

29.

Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.

Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, Guchelaar HJ, Reyners AK, van Herpen CM, Haanen JB, Mathijssen RH, Boven E.

Clin Pharmacol Ther. 2012 Oct;92(4):503-10. doi: 10.1038/clpt.2012.136. Epub 2012 Sep 5.

PMID:
22948895
30.

Bevacizumab in neoadjuvant treatment for breast cancer.

van der Veldt AA, Smit EF.

N Engl J Med. 2012 Apr 26;366(17):1637; author reply 1638-40. doi: 10.1056/NEJMc1202229. No abstract available.

PMID:
22533581
31.

Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.

Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE.

Eur Urol. 2012 Oct;62(4):685-95. doi: 10.1016/j.eururo.2012.01.020. Epub 2012 Jan 23.

PMID:
22285764
32.

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA, Smit EF.

Cancer Cell. 2012 Jan 17;21(1):82-91. doi: 10.1016/j.ccr.2011.11.023.

33.

Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer.

van der Veldt AA, Vroling L, de Haas RR, Koolwijk P, van den Eertwegh AJ, Haanen JB, van Hinsbergh VW, Broxterman HJ, Boven E.

Int J Cancer. 2012 Aug 15;131(4):E484-93. doi: 10.1002/ijc.26456. Epub 2011 Nov 8.

34.

Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography.

van der Veldt AA, Lubberink M, Greuter HN, Comans EF, Herder GJ, Yaqub M, Schuit RC, van Lingen A, Rizvi SN, Mooijer MP, Rijnders AY, Windhorst AD, Smit EF, Hendrikse NH, Lammertsma AA.

Clin Cancer Res. 2011 Jul 15;17(14):4814-24. doi: 10.1158/1078-0432.CCR-10-2933. Epub 2011 Jul 12.

35.

Comment on Cho et al.: Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction.

van der Veldt AA, Lubberink M, Lammertsma AA, Smit EF.

Eur Radiol. 2011 Oct;21(10):2148-9; author reply 2150. doi: 10.1007/s00330-011-2172-9. Epub 2011 Jun 18. No abstract available.

36.

Advances in pancreatic neuroendocrine tumor treatment.

van der Veldt AA, Kleijn SA.

N Engl J Med. 2011 May 12;364(19):1873; author reply 1873-5. doi: 10.1056/NEJMc1102746. No abstract available.

PMID:
21561355
37.

Targeted therapy for renal cell cancer: current perspectives.

van der Veldt AA, Haanen JB, van den Eertwegh AJ, Boven E.

Discov Med. 2010 Nov;10(54):394-405. Review.

38.

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.

van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, van den Eertwegh AJ, Haanen JB, Mathijssen RH, Wessels JA.

Clin Cancer Res. 2011 Feb 1;17(3):620-9. doi: 10.1158/1078-0432.CCR-10-1828. Epub 2010 Nov 19.

39.

Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer.

van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, Lammertsma AA, Lubberink M.

J Nucl Med. 2010 Nov;51(11):1684-90. doi: 10.2967/jnumed.110.079137. Epub 2010 Oct 18.

40.

Perfusion CT and US of colorectal cancer liver metastases: a correlative study of two dynamic imaging modalities.

Meijerink MR, van Waesberghe JH, van Schaik C, Boven E, van der Veldt AA, van den Tol P, Meijer S, van Kuijk C.

Ultrasound Med Biol. 2010 Oct;36(10):1626-36. doi: 10.1016/j.ultrasmedbio.2010.06.015.

PMID:
20800954
41.

Myelosuppression by sunitinib is flt-3 genotype dependent.

van Erp NP, Mathijssen RH, van der Veldt AA, Haanen JB, Reyners AK, Eechoute K, Boven E, Wessels JA, Guchelaar HJ, Gelderblom H.

Br J Cancer. 2010 Aug 24;103(5):757-8. doi: 10.1038/sj.bjc.6605813. Epub 2010 Aug 3. No abstract available.

42.

Targeted therapies in renal cell cancer: recent developments in imaging.

van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E.

Target Oncol. 2010 Jun;5(2):95-112. doi: 10.1007/s11523-010-0146-5. Epub 2010 Jul 14. Review.

43.

Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon.

de Boer MP, van der Veldt AA, Lankheet NA, Wijnstok NJ, van den Eertwegh AJ, Boven E, Serné EH.

Ann Oncol. 2010 Sep;21(9):1923-4. doi: 10.1093/annonc/mdq335. Epub 2010 Jul 5. No abstract available.

PMID:
20603433
44.

Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients.

van der Veldt AA, Hendrikse NH, Smit EF, Mooijer MP, Rijnders AY, Gerritsen WR, van der Hoeven JJ, Windhorst AD, Lammertsma AA, Lubberink M.

Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1950-8. doi: 10.1007/s00259-010-1489-y. Epub 2010 May 27.

45.

Re: Surgical resection of renal cell carcinoma after targeted therapyA. A. Thomas, B. I. Rini, A. J. Stephenson, J. A. Garcia, A. Fergany, V. Krishnamurthi, A. C. Novick, I. S. Gill, E. A. Klein, M. Zhou and S. C. Campbell J Urol 2009; 182: 881-886.

Bex A, van der Veldt AA, Boven E, Haanen JB.

J Urol. 2010 Apr;183(4):1646-7; author reply 1647. doi: 10.1016/j.juro.2009.12.047. Epub 2010 Feb 21. No abstract available.

PMID:
20176381
46.

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E.

Br J Cancer. 2010 Mar 2;102(5):803-9. doi: 10.1038/sj.bjc.6605567. Epub 2010 Feb 9.

47.

Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.

Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB.

Acta Oncol. 2010 May;49(4):520-3. doi: 10.3109/02841860903521111. No abstract available.

PMID:
20105087
48.

Re: Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence and disease pattern.

van der Veldt AA, Comans EF, Thunnissen FB, Hendrikse NH, Smit EF, van der Hoeven JJ.

Clin Radiol. 2010 Jan;65(1):94-6; author reply 96-7. doi: 10.1016/j.crad.2009.08.011. Epub 2009 Nov 11. No abstract available.

PMID:
20103429
49.

Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib.

van der Veldt AA, de Boer MP, Boven E, Eringa EC, van den Eertwegh AJ, van Hinsbergh VW, Smulders YM, Serné EH.

Anticancer Drugs. 2010 Apr;21(4):439-46. doi: 10.1097/CAD.0b013e3283359c79.

PMID:
20051825
50.

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H.

J Clin Oncol. 2009 Sep 10;27(26):4406-12. doi: 10.1200/JCO.2008.21.7679. Epub 2009 Aug 10. Erratum in: J Clin Oncol. 2010 Jun 1;28(16):2805.

PMID:
19667267

Supplemental Content

Loading ...
Support Center